Who Paid My Doc
Vandely Perez
General Practice Hialeah, FL
NPI 1003848268 CMS profile 847244
5378 W 16Th Ave, Hialeah, FL 33012
General payments
$0
Research payments
$0
Ownership & investment interest
$0
The CMS Open Payments record contains no reported payments to Vandely Perez of Hialeah, FL.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
Prescribing to Medicare patients
Part D · data year 2024 · 135 drugsPart D claims
6,615
Drug cost
$554,517
Branded share of claims
20.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 91 | $90,143 | |
| Eliquis Apixaban | Brand | 67 | $82,584 | |
| Januvia Sitagliptin Phosphate | Brand | 44 | $54,791 | |
| Entresto Sacubitril/Valsartan | Brand | 48 | $47,601 | |
| Xarelto Rivaroxaban | Brand | 29 | $43,530 | |
| Farxiga Dapagliflozin Propanediol | Brand | 42 | $30,818 | |
| Veltassa Patiromer Calcium Sorbitex | Brand | 24 | $24,229 | |
| Jardiance Empagliflozin | Brand | 13 | $18,193 | |
| Linzess Linaclotide | Brand | 21 | $17,904 | |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | Brand | 27 | $16,856 |
The 10 drugs with the highest cost, of 135 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Related records
General Practice in Florida
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.